NCT01123772 is a Phase 1 clinical trial of INO-8875 in Health, sponsored by Inotek Pharmaceuticals Corporation.

Who is sponsoring NCT01123772?

NCT01123772 is sponsored by Inotek Pharmaceuticals Corporation.

What drugs are being tested in NCT01123772?

Interventions in NCT01123772: INO-8875, Placebo control.

Is NCT01123772 still recruiting?

NCT01123772 is currently completed. Last updated 27 April 2012.

Last reviewed 2012-04-27 · How we verify

NCT01123772

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I, Randomized, Double-Masked, Placebo-Controlled, Dose-Escalation Study to Evaluate Tolerability, Safety & PK of BID Topical Ocular Application of INO-8875 in Healthy Older-Adult Volunteers

Completed Phase 1 Last updated 27 April 2012

What this trial tests

Phase 1 trial testing INO-8875 in Health in 70 participants. Completed in 1 February 2011.

Timeline

1 May 2010

Primary endpoint
1 February 2011

1 February 2011

Quick facts

Lead sponsor	Inotek Pharmaceuticals Corporation
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	70
Start date	1 May 2010
Primary completion	1 February 2011
Estimated completion	1 February 2011
Sites	1 location across United States

Drugs / interventions tested

INO-8875 — full drug profile →
Placebo control

Conditions studied

Health — all drugs for Health →

Sponsor

Inotek Pharmaceuticals Corporation — full company profile →

Who can join

Adults 35 to 65, any sex, with Health. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time frame: 14 days

Sponsor's own description

The purpose of this study is to evaluate how tolerable and safe it is to give INO-8875 eye drops at different concentrations to normal older healthy adult volunteers for two weeks.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Potential for developing purinergic drugs for gastrointestinal diseases.
Ochoa-Cortes F, Liñán-Rico A, Jacobson KA, Christofi FL. · · 2014 · cited 46× · PMID 24859298 · DOI 10.1097/mib.0000000000000047
Targeting Schlemm's Canal in the Medical Therapy of Glaucoma: Current and Future Considerations.
Andrés-Guerrero V, García-Feijoo J, Konstas AG. · · 2017 · cited 26× · PMID 28349508 · DOI 10.1007/s12325-017-0513-z
A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult Volunteers.
Laties A, Rich CC, Stoltz R, Humbert V, et al · · 2016 · cited 14× · PMID 27046445 · DOI 10.1089/jop.2015.0147

Verify or expand the search:

Other recruiting trials for Health

Currently open trials in the same condition.

NCT07356492 — Expanding Veteran Sponsorship Initiative+ to Support High-Risk Transitioning Servicemembers and Veterans: A Precision Me · NA · recruiting
NCT06854536 — A Study on the Changes and Prognosis of Intestinal Microbiota and Function in Infants With Food Allergies · active not recruiting
NCT06691100 — How a Single Workout Affects Gut Bugs in Women With Different Fitness Levels and Body Types · NA · recruiting
NCT06360055 — Effect of Oral D-mannose Tablets on Pharmacokinetics of Dabigatranate in Healthy Adults · NA · recruiting
NCT06157346 — Characteristics of Intestinal Bacteria and Their Effects on Growth and Immune Function in Children at High Altitude · recruiting

Other Inotek Pharmaceuticals Corporation trials

Trials by the same sponsor.

NCT02829996 — Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01123772 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Inotek Pharmaceuticals Corporation
Last refreshed: 27 April 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01123772.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing